CD45 as a multifunctional target in immune regulation and therapeutic delivery Authors: Kaikai Zhao, Ruohan Yang, Mengli Li, Zhenzhong Zhang, Junjie Liu, Jinjin Shi, Xiu Zhao Published: 2026 ABSTRACT BackgroundCD45, a receptor-type protein tyrosine phosphatase broadly expressed on leukocytes, is a critical regulator of signaling thresholds and immune cell activation. Dysregulation of CD45 has been implicated in a range of immune-related diseases and malignancies.Main bodyRecent advances have focused on modulating CD45 for disease treatment through various strategies, including regulating its expression level, structural conformation, and spatial membrane distribution. Beyond the immunomodulatory role, as a leukocyte-specific and broadly expressed biomarker, CD45 also has broad application in the field of drug delivery, such as the development of CD45 antibody-drug conjugates and a drug-loading site on live-cell carriers.ConclusionsThis review systematically summarizes the immunoregulatory mechanisms of CD45 across various immune cell subsets and discusses CD45-based therapeutic interventions and drug delivery strategies, bridging basic immunology with therapeutic advancement. Introduction CD45, also known as leukocyte common antigen, is a receptor-type protein tyrosine phosphatase abundantly expressed on the surface of all nucleated hematopoietic cells, accounting for approximately 5–10% of lymphocyte membrane glycoproteins [1–3]. Structurally, CD45 consists of a highly glycosylated extracellular domain, a single transmembrane helix, and a conserved intracellular phosphatase domain [4]. The extracellular domain is highly glycosylated, maintaining membrane stability and regulating interactions with other membrane proteins and extracellular ligands. The transmembrane region consists of a single α-helix that firmly anchors CD45 within the lipid bilayer and modulates intracellular–substrate contact efficiency through conformational adjustments. The intracellular domain contains two conserved phosphatase subdomains (D1/D2): D1 harbors the catalytic cysteine- and arginine-containing active site responsible for substrate dephosphorylation, while D2 modulates D1 activity through conformational regulation [5]. Its cytoplasmic domain regulates immune signaling by modulating Src family kinases such as lymphocyte-specific protein tyrosine kinase (Lck) ( Key abbreviations used in this review are listed in Table 1.), acting either to promote or suppress signaling depending on cellular context [6–10]. Additionally, CD45 dephosphorylates Janus kinases (JAKs), functioning as a negative regulator of cytokine signaling [11]. Table 1List of abbreviationsAbbreviation Full Name ABEAdenine base editingADCAntibody–drug conjugateARCAntibody–radionuclide conjugateApt-RIPRAptamer-based phosphatase-recruiting chimeraBCRB cell receptorCAR-T cellChimeric antigen receptor T cellcSMACCentral supramolecular activation clusterCTLA-4Cytotoxic T lymphocyte-associated antigen 4CTCCirculating tumor cellDCDendritic cellEVExtracellular vesicleERKExtracellular signal-regulated kinaseFAKFocal adhesion kinaseGPCRG protein-coupled receptorGSK-3Glycogen synthase kinase-3GVHDGraft-versus-host diseaseHSCHematopoietic stem cellIFNInterferonILInterleukinIL-15SaIL-15 superagonistITAMImmunoreceptor tyrosine-based activation motifITIMImmunoreceptor tyrosine-based inhibitory motifITSMImmunoreceptor tyrosine-based switch motifJAKJanus kinaseJNKc-Jun N-terminal kinaseLdLipid-disorderedLNPLipid nanoparticleLoLipid-orderedLPSLipopolysaccharideLckLymphocyte-specific protein tyrosine kinaseMAPKMitogen-activated protein kinaseMHCMajor histocompatibility complexMLVMultilamellar liposomeNGNanogelNK cellNatural killer cellNKRNatural killer receptorNF-κBNuclear factor-κBNHS-SS-NHSN-hydroxysuccinimide-SS-N-hydroxysuccinimidePD-1Programmed death-1PBDPyrrolo[3,4-b]quinazolinePI3KPhosphatidylinositol 3-kinasePLCγPhospholipase CγPTPRFProtein tyrosine phosphatase receptor type FpSMACPeripheral supramolecular activation clusterROSReactive oxygen speciesRTKReceptor tyrosine kinaseRNAiRNA InterferencescFvSingle-chain variable fragmentSFKSrc family kinaseSIRPαSignal regulatory protein αsiRNASmall interfering RNASTATSignal transducer and activator of transcriptionTCRT cell receptorTAMTumor-associated macrophageTim-3T cell immunoglobulin and mucin domain-containing protein 3TRMTissue-resident memory T cellVEGFVascular endothelial growth factorVHHSingle-domain antibody Table 1List of abbreviationsAbbreviation Full Name ABEAdenine base editingADCAntibody–drug conjugateARCAntibody–radionuclide conjugateApt-RIPRAptamer-based phosphatase-recruiting chimeraBCRB cell receptorCAR-T cellChimeric antigen receptor T cellcSMACCentral supramolecular activation clusterCTLA-4Cytotoxic T lymphocyte-associated antigen 4CTCCirculating tumor cellDCDendritic cellEVExtracellular vesicleERKExtracellular signal-regulated kinaseFAKFocal adhesion kinaseGPCRG protein-coupled receptorGSK-3Glycogen synthase kinase-3GVHDGraft-versus-host diseaseHSCHematopoietic stem cellIFNInterferonILInterleukinIL-15SaIL-15 superagonistITAMImmunoreceptor tyrosine-based activation motifITIMImmunoreceptor tyrosine-based inhibitory motifITSMImmunoreceptor tyrosine-based switch motifJAKJanus kinaseJNKc-Jun N-terminal kinaseLdLipid-disorderedLNPLipid nanoparticleLoLipid-orderedLPSLipopolysaccharideLckLymphocyte-specific protein tyrosine kinaseMAPKMitogen-activated protein kinaseMHCMajor histocompatibility complexMLVMultilamellar liposomeNGNanogelNK cellNatural killer cellNKRNatural killer receptorNF-κBNuclear factor-κBNHS-SS-NHSN-hydroxysuccinimide-SS-N-hydroxysuccinimidePD-1Programmed death-1PBDPyrrolo[3,4-b]quinazolinePI3KPhosphatidylinositol 3-kinasePLCγPhospholipase CγPTPRFProtein tyrosine phosphatase receptor type FpSMACPeripheral supramolecular activation clusterROSReactive oxygen speciesRTKReceptor tyrosine kinaseRNAiRNA InterferencescFvSingle-chain variable fragmentSFKSrc family kinaseSIRPαSignal regulatory protein αsiRNASmall interfering RNASTATSignal transducer and activator of transcriptionTCRT cell receptorTAMTumor-associated macrophageTim-3T cell immunoglobulin and mucin domain-containing protein 3TRMTissue-resident memory T cellVEGFVascular endothelial growth factorVHHSingle-domain antibody List of abbreviations Abnormalities in CD45 expression or function are implicated in a range of immune-related diseases and malignancies. CD45-deficient mice display impaired natural killer cell function, reduced antiviral immunity, and heightened tumor susceptibility [12]. Alternative splicing of the CD45 gene gives rise to multiple isoforms such as CD45RA, RB, and RO. CD45RA, containing exons 4–6, is mainly expressed on naïve T cells, B cells, and some natural killer (NK) cells. Its larger extracellular domain limits proximity to signaling molecules, resulting in lower phosphatase activity. CD45RO that lacks exons 4–6 is abundant in activated and memory T cells as well as mature dendritic cells (DCs), and exhibits higher catalytic activity due to reduced steric hindrance, thus playing a key role in sustaining immune activation. CD45RB, containing only exon 5, is expressed in transitional T/B cell subsets with intermediate phosphatase activity [13] These isoforms differ in function and tissue distribution and have been linked to immune dysregulation and autoimmunity. For instance, an imbalance in the CD45RA/RO ratio in T cells disrupts activation threshold regulation and contributes to systemic lupus erythematosus [14]. In addition, as a key protein tyrosine phosphatase, the spatial distribution of CD45 on the plasma membrane directly affects its efficiency in dephosphorylating nearby immune receptor–associated substrates, thus participating in the balance between activation and inhibition of immune signaling [15]. Therefore, CD45 represents a promising therapeutic target, and modulating its expression levels, isoform composition, and membrane distribution may offer effective strategies for disease treatment. Beyond its role as a signaling modulator, CD45 offers unique advantages as a target for therapeutic delivery systems. Its high expression on hematopoietic cells and conserved glycosylation epitopes facilitate antibody engineering and improve specificity. CD45-targeted strategies, such as antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), and immunocytokine fusions, have shown promise in eliminating leukemic cells with minimal off-target effects. Furthermore, the stable surface expression and low endocytic turnover of CD45 make it a valuable anchor for live-cell drug delivery platforms using leukocytes as biological carriers [16]. This review highlights the multifaceted biological functions of CD45 in immune regulation and tumor biology, evaluates its potential as a therapeutic target, and explores its expanding applications in targeted and cell-based drug delivery. By linking molecular insights with translational strategies, we aim to provide a framework for future development of CD45-centered immunotherapies (Fig. 1). Fig. 1Schematic illustration of the multidimensional applications of CD45 protein in disease therapy and drug delivery. Figure is created using BioRender (https://www.biorender.com/) Schematic illustration of the multidimensional applications of CD45 protein in disease therapy and drug delivery. Figure is created using BioRender (https://www.biorender.com/) Biological functions of CD45 in leukocytes and tumor cells T cells The central role of CD45 in T cell activation was first elucidated through investigations on TCR signaling pathways. Genetic evidence has demonstrated that CD45-deficient T cells are incapable of initiating TCR signal transduction [17], underscoring its indispensable role in the signaling cascades [18]. In resting T cells, CD45 maintains TCR signaling homeostasis by dynamically modulating the phosphorylation status of two key substrates. On the one hand, CD45 dephosphorylates the inhibitory tyrosine residue (Y505) of Lck kinase, thereby releasing it from its autoinhibited conformation [19, 20]. Activated Lck then phosphorylates the tyrosine residues in the immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3ζ subunit, thus initiating the downstream immune signaling cascade [21]. On the other hand, it can prevent premature activation of TCR signaling by dephosphorylating the ITAMs on the CD3ζ subunit [22]. This bidirectional regulatory mechanism ensures that TCR signaling is maintained in a controlled “primed” state. When T cells encounter antigen-presenting cells presenting cognate antigens, CD45 is excluded from the central supramolecular activation complex (cSMAC) at the immunological synapse, where TCR and co-stimulatory molecules are concentrated [23, 24]. This exclusion reduces its dephosphorylation activity towards the ITAMs on CD3ζ, leading to the recruitment and activation of downstream kinases such as ZAP-70, and the subsequent activation of signaling cascades including phospholipase Cγ (PLC-γ), nuclear factor-κB (NF-κB), and mitogen-activated protein kinase (MAPK) [25], which are crucial for T cell proliferation, differentiation, and effector function. Aberrant expression or dysfunction of CD45 plays a pivotal role in various T cell-associated diseases. For example, T cells in the synovial fluid of patients with rheumatoid arthritis exhibit markedly reduced CD45 phosphatase activity, likely due to oxidative inactivation by reactive oxygen species in the synovial microenvironment. This inactivation leads to attenuated calcium responses to anti-CD3 stimulation, and a significant proportion of T cells lose responsiveness [26, 27]. Genetic studies have further revealed that the C77G point mutation in exon 4 (exon A) of CD45 is rare in the general population (0–3.5%), while significantly enriched in patients with multiple sclerosis [28], systemic lupus erythematosus [29], and hepatitis C [30, 31]. The C77G mutation on CD45 improved the activity of LFA-1 (CD11a/CD18) on T cells by altering CD45-mediated signaling, enhancing integrin-dependent adhesion to endothelial intercellular adhesion molecule-1. This facilitates transendothelial migration and subsequent T cell infiltration into inflamed tissues, such as the central nervous system in multiple sclerosis [32]. B cells CD45 plays a crucial role in B cell activation, and its functional mechanisms closely resemble those in T cells [18]. Under resting conditions, CD45 dephosphorylates the inhibitory tyrosine residue (Y507) at the C-terminus of the Lyn kinase, thereby relieving its autoinhibitory conformation and allowing autophosphorylation at the activating site Y397. This maintains Lyn in a “primed” state, enabling a rapid response to external antigens [33–36]. Upon antigen-induced clustering of B cell receptors (BCRs), these microclusters, typically located at the tips of membrane microvilli, actively exclude CD45 due to its large extracellular domain. This “kinetic segregation” physically limits CD45-mediated dephosphorylation of ITAMs on the BCR complex. Meanwhile, CD45 molecules outside the BCR microclusters can continue to dephosphorylate Y507 of nearby Lyn kinases, maintaining their active state. Activated Lyn subsequently phosphorylates ITAMs on Igα/Igβ, recruiting and activating Syk kinase. Syk then phosphorylates the adaptor protein BLNK, leading to the activation of PLCγ2, which generates the second messengers IP3 and DAG. This cascade induces intracellular Ca2+ release and activates the PKC and Ras-MAPK pathways, ultimately leading to the activation of transcription factors NF-κB and NFAT that drive B cell proliferation and differentiation [37–41]. The spatial distribution of CD45 on the membrane and its dynamic phosphatase activity constitute a finely tuned signaling system, enabling B cells to rapidly and efficiently initiate immune responses upon antigen recognition. CD45 also plays significant roles in various B cell-related diseases. In diffuse large B-cell lymphoma, tumor cells upregulate CD45 expression and utilize it as a membrane receptor for galectin-3, enhancing anti-apoptotic signaling and thereby increasing tumor cell survival [42–44]. Additionally, CD45 is involved in the development and progression of atherosclerosis. Ma et al. reported that downregulation of CD45 impairs its ability to dephosphorylate the inhibitory site Y507 of Lyn kinase, resulting in Lyn being locked in an autoinhibitory conformation. Even when the activating loop residue Y397 is phosphorylated, Lyn remains functionally inactive, thereby disrupting BCR signaling and attenuating B cell activation. Ultimately, this inhibits the formation of atherosclerotic plaques [45]. In summary, the function of CD45 in B cells is not only dependent on its phosphatase activity and regulation of Src family kinases (SFKs) but also influenced by the local microenvironment, which may alter its functional properties under pathological conditions. NK cells The primary role of CD45 in NK cells is to regulate ITAM-dependent signaling pathways, thereby influencing degranulation, cytokine secretion, and cellular expansion. Specifically, CD45 continuously dephosphorylates the C-terminal inhibitory tyrosine residues of SFKs, such as Tyr507 of Lyn and Tyr537 of Hck, relieving their autoinhibitory conformations and maintaining basal kinase activity, which primes the cell for receptor-induced signaling [46–48]. Upon engagement of activating receptors on the NK cell surface (e.g., CD16, NKG2D, Ly49D/H, NKp46) with ITAM-containing adaptor proteins (such as DAP12 or FcεRIγ), the SFKs maintained in a basal active state by CD45 undergo autophosphorylation at activation loop residues (e.g., Tyr397 of Lyn, Tyr419 of Fyn), thereby fully activating their kinase function. The activated SFKs then phosphorylate tyrosine residues within the ITAMs, creating docking sites for the recruitment of Syk kinase. Thus, by positively regulating SFK enzymatic activity, CD45 indirectly promotes ITAM phosphorylation. Phosphorylated ITAMs subsequently recruit and activate Syk, which phosphorylates downstream adaptor proteins LAT and SLP-76, leading to the activation of PLCγ and the Ras-MAPK pathways (including ERK, JNK, and p38). These cascades ultimately drive the release of cytotoxic granules (such as perforin and granzymes) and the transcription and secretion of cytokines such as interferon-γ (IFN-γ) [49, 50]. In CD45-deficient mouse models, NK cells retain the ability to produce IFN-γ in response to inflammatory cytokines such as interleukin-12 (IL-12) and IL-18; however, their ITAM-dependent degranulation and cytokine secretion functions are markedly impaired, highlighting the essential role of CD45 in receptor-mediated effector responses [51]. DCs CD45 plays a critical role in regulating signal transduction and immune functions in DCs. Its tyrosine phosphatase activity primarily modulates the phosphorylation status of SFKs, including Lyn, Hck, and Fyn, thereby affecting the responsiveness of DCs to Toll-like receptor (TLR) signaling. Upon stimulation of TLRs by exogenous ligands, CD45 dephosphorylates the inhibitory site Tyr507 of Lyn, relieving its autoinhibitory conformation and maintaining basal SFK activity, which facilitates the initial activation of TLR signaling. However, under strong stimulation by TLR agonists such as lipopolysaccharide (LPS), CD45 can also dephosphorylate the activating site Tyr397 of Lyn, thereby limiting its hyperactivation and restraining excessive inflammatory responses [52]. CD45 also influences the selective activation of distinct TLR pathways, exhibiting notable pathway specificity. Studies have shown that CD45 positively regulates the MyD88-independent pathways mediated by TLR3 and TLR4, enhancing the production of type I interferons such as IFN-β. In contrast, during TLR2- and TLR9-induced MyD88-dependent signaling, CD45 predominantly suppresses Lyn activity, thereby reducing the secretion of proinflammatory cytokines such as IL-6 and TNF-α. These findings indicate that CD45 contributes to antiviral immunity while simultaneously suppressing excessive proinflammatory responses, thereby maintaining functional balance in DCs [53–55]. Collectively, by modulating SFK activity and finely tuning both the strength and pathway specificity of TLR signaling, CD45 serves as a key regulatory factor in balancing proinflammatory responses and immune homeostasis in DCs. Macrophages In macrophages, CD45 distinctly regulates SFKs, primarily by limiting the activities of Hck and Lyn to maintain the homeostasis of integrin-mediated adhesion signaling [56–58]. Upon ligand binding to Mac-1 integrins, Hck and Lyn undergo autophosphorylation at their activation loop site Tyr416, leading to the phosphorylation of focal adhesion kinase (FAK) at Tyr397 and subsequent phosphorylation of the adhesion protein paxillin at Ser83, thereby promoting cell spreading and adhesion [59]. CD45 attenuates the kinase activities of Hck and Lyn by dephosphorylating their Tyr416 residues, and concurrently dephosphorylates FAK at Tyr397, thereby preventing the excessive maturation of focal adhesions [60–62]. In the absence of CD45, Hck and Lyn exhibit hyperactivation, resulting in sustained phosphorylation of FAK and paxillin, which ultimately causes dysregulation of integrin-dependent adhesion and impaired cell migration [63]. In addition to adhesion-related signaling, CD45 negatively regulates the janus kinases (JAK)-signal transducer and activator of transcription (STAT) pathway and contributes to macrophage phenotype polarization. Upon stimulation by cytokines such as IL-6, JAKs phosphorylate STAT3 at Tyr705, leading to STAT3 dimerization and the initiation of gene transcription associated with tumor-associated macrophage (TAM) differentiation. CD45 directly dephosphorylates STAT3 at Tyr705, thereby blocking its activation and suppressing the expression of TAM-promoting genes such as IL-10 and VEGF [64]. Neutrophils CD45 plays a critical role in neutrophil chemotaxis, adhesion, and migration by modulating the activity of SFKs, and also contributes to actin cytoskeleton remodeling through regulation of small GTPases such as Rac2, thereby supporting cellular functions such as migration, phagocytosis, and degranulation. These mechanisms collectively ensure effective neutrophil migration and responsiveness upon external stimulation [65, 66]. For example, CD45 enhances the production of reactive oxygen species (ROS) in response to neutrophil-activating stimuli, including chemokines, and promotes G protein-coupled receptor (GPCR)-mediated signaling, increasing intracellular Ca2+ mobilization and activating key downstream pathways such as phosphatidylinositol 3-kinase (PI3K) and extracellular signal-regulated kinase (ERK), thereby facilitating directional cell migration [67, 68]. CD45 can also interact directly with receptor complexes of inflammatory mediators such as leukotriene B4 and complement component C5a, modulating neutrophil chemotactic responses to these ligands [69]. Moreover, CD45 indirectly regulates integrin-associated vesicular trafficking and transendothelial migration through the activation of SFKs. When CD45 function is dysregulated, neutrophil migratory capacity becomes impaired [70]. Studies have shown that neutrophils harboring a point mutation in CD45 (E613R) exhibit aberrant phosphatase activity, resulting in sustained activation of SFKs such as Lyn and Fgr. This leads to an imbalanced integrin phenotype, characterized by increased LFA-1 affinity but impaired adhesive function, and markedly elevated Mac–1–mediated adhesion. Excessive Mac-1 mediated adhesion causes neutrophils to become overly anchored to the vascular endothelium, while defective LFA-1 adhesion impairs initial tethering. These defects disrupt the dynamic adhesion–detachment–migration cycle, severely impairing intravascular crawling, reducing transendothelial migration efficiency, and ultimately diminishing neutrophil recruitment to sites of inflammation [71]. These findings highlight CD45 as a critical regulator of neutrophil adhesion–migration dynamics and suggest it as a potential therapeutic target for modulating neutrophil trafficking in inflammatory diseases. Tumor cells CD45, as a classic immune cell marker, has recently been found to be ectopically expressed on the surface of solid tumor cells. Notably, accumulating evidence from multiple independent studies suggests that this phenomenon is not restricted to specific tumor types but occurs across a broad spectrum of malignancies, particularly in circulating tumor cells. The aberrant expression of CD45 on tumor cells may contribute to immune escape mechanisms, providing a novel biological basis for tumor treatment. For example, Danbara et al. successfully identified CD45+ tumor cells in the bone marrow micrometastases of an small cell lung cancer patient via flow cytometry. Notably, the primary tumor cells were CD45-negative, suggesting that CD45 may be acquired during the metastatic process through phenotypic remodeling, potentially involving CD45-mediated adhesion or survival signaling pathways [72]. Yang et al. reported that CD45+ circulating tumor cells (CTCs) are prevalent in patients with colorectal, non-small cell lung cancers, and hepatocellular carcinoma, and their frequency correlates with metastasis and poor prognosis. Further investigation revealed that CTCs could acquire CD45 from immune cell-derived extracellular vesicles (EVs). CD45 on tumor cells formed homodimers with CD45 on T cells, disrupting its exclusion from the TCR-pMHC synapse and inhibiting phosphorylation of key signaling molecules, such as CD3G and ZAP-70, thereby attenuating T cell activation. Animal models had confirmed the enhanced metastatic potential of CD45+ CTCs in immunocompetent mice, and intratumoral injection of CD45+ EVs remodeled the immunosuppressive microenvironment. Single-cell copy number variation analysis and patient-derived xenograft models further corroborated the malignant and pro-metastatic nature of CD45+ CTCs [73]. This study provides a theoretical basis for strategies targeting CD45 internalization or disrupting CD45 homodimerization to inhibit metastasis. Furthermore, in colorectal cancer, Shin et al. found that tumor cells were capable of acquiring immunoregulatory molecules such as CD45 from tumor-infiltrating lymphocytes via trogocytosis, which were acquired upon cell–cell contact. Mechanistically, this transfer depended on actin polymerization and PI3K signaling. In vitro culture of sorted CD45+ colorectal cancer cells showed that CD45 expression was lost within days, while tumor-specific markers remained stable. Thus, CD45 expression in tumor cells was short-lived rather than persistent or genetically fixed. In vivo experiments further showed that CD45+ tumor cells strongly suppressed T cell activation, indicating their immune evasion function [74]. Park and colleagues showed that CD45 was upregulated in chemotherapy-resistant colorectal cancer stem cells, correlating with tumor recurrence and metastasis. Mechanistically, CD45 enhanced Wnt/β-catenin signaling by dephosphorylating β-catenin, preventing its ubiquitin-mediated degradation and promoting cancer stemness and chemoresistance. This finding suggests that, in a subset of tumor stem-like populations, CD45 may retain enzyme phosphatase activity and actively participate in oncogenic signaling rather than just acting as an immune camouflage marker [75]. Overall, CD45 has been observed across multiple solid tumor types, including colorectal cancer, small cell lung cancer, non-small cell lung cancer, and hepatocellular carcinoma. Current evidence suggests that tumor cells predominantly acquire CD45 through EVs transfer or trogocytosis rather than endogenous expression, and its presence on the tumor cell surface is typically transient rather than stably maintained. Functionally, CD45 primarily acts as an immune camouflage mechanism that induce immune escape. Emerging data further indicate that in certain tumor subpopulations, such as chemotherapy-resistant cancer stem-like cells, CD45 may retain phosphatase activity and participate in oncogenic signaling pathways. In summary, CD45, as a signal threshold regulator, plays a crucial role in immune regulation across various immune cell types. In lymphocytes such as T cells, B cells, and NK cells, CD45 predominantly supports rapid immune activation by maintaining Src family kinases in a signal ready state while dynamically regulating receptor phosphorylation. In contrast, in myeloid cells including DCs, macrophages, and neutrophils, CD45 typically acts as a negative regulator factor, preventing excessive inflammation, adhesion, or migration reactions by inhibiting kinase overactivation and downstream pathway amplification. These distinct functional outcomes arise from differences in substrate distribution, membrane topology, and lineage-specific signaling networks. In addition, the disguised CD45 on tumor cells can participate in immune escape and tumor progression. CD45 regulatory strategy for disease treatment As described in the first section, CD45 plays a pivotal role in regulating immune signaling. Its aberrant expression, structural alterations, and changes in membrane localization have been implicated in various diseases, including autoimmune disorders and hematological malignancies. Therefore, functional modulation of CD45 has emerged as a promising therapeutic strategy, primarily involving gene editing to regulate its expression levels, structural modifications, and spatial distribution on the cell membrane. Specific regulatory approaches will be discussed in the following section. Modulating the expression level of CD45 protein As a core member of the receptor-type protein tyrosine phosphatase family, CD45 precisely controls the activation threshold of lymphocytes [76]. Its expression level directly determines the signal transduction [77]. RNA interference (RNAi)-based gene silencing technology has shown distinct advantages in regulating CD45 protein expression levels. For example, Novobrantseva et al. developed a lipid nanoparticle (LNP) delivery system, which efficiently and durably silenced CD45 protein in myeloid cells by encapsulating CD45-targeted small interfering RNA (siRNA). Mechanistically, LNP-siRNA entered the cells via macrophage phagocytosis, inducing RNAi-specific cleavage of CD45 mRNA at the target site (CTGGCTGAA/TTTCAGAGCA). Sequencing results confirmed that more than 95% of cleavage products were detected. In vivo experiments indicated that CD45 protein silencing in macrophage lineages (e.g., peritoneal cavity and splenic macrophages) reached 80–90% and lasted for more than three weeks following a single dose. Notably, this modulation was highly cell-specific: the silencing rate in DCs was approximately 40%, while T cells, NK cells, and other immune cells were unaffected, thereby preventing interference with protective immune functions. Moreover, CD45 protein silencing in blood, spleen, and liver myeloid cells ranged from 30% to 60% in non-human primates. This study demonstrated the feasibility of precise modulation of myeloid cell functions by adjusting CD45 expression, offering an effective strategy for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (Fig. 2) [78]. Fig. 2(A–C) LNP-siRNA mediated efficient and durable silencing of CD45 protein in murine myeloid cells. (D) In vivo silencing of CD45 protein in myeloid cells of non-human primates. Adapted from Novobrantseva et al. [78] Copyright 2012 Mol. Ther. Nucl. Acids (A–C) LNP-siRNA mediated efficient and durable silencing of CD45 protein in murine myeloid cells. (D) In vivo silencing of CD45 protein in myeloid cells of non-human primates. Adapted from Novobrantseva et al. [78] Copyright 2012 Mol. Ther. Nucl. Acids Structural regulation of CD45 Structural biology studies have revealed that the structure of CD45 plays a critical role in its phosphatase activity [79]. For example, different isoforms of CD45 exhibit distinct topological conformations near the membrane, thereby affecting its catalytic activity and immune receptor signaling thresholds [18, 80]. The RO isoform (lacking exons 4, 5, and 6) with its compact extracellular domain readily forms homodimers in the juxtamembrane region. This dimeric conformation sterically hinders substrate access to the catalytic D1 domain and consequently reduces dephosphorylation efficiency [81, 82]. In contrast, larger isoforms like RABC possess bulky O-glycosylated extensions encoded by the variable exons, which serve as a steric barrier to homodimerization and promote a monomeric state. This monomeric conformation maintains an open and accessible catalytic site, facilitating efficient substrate engagement [83, 84]. Therefore, maintaining CD45 in its monomeric form on the cell membrane is essential for its catalytic function. Moreover, Xiao et al. sought to modulate the molecular size of CD45 for enhancing chimeric antigen receptor T (CAR-T) cell activation. During CAR-T cell activation, CD45 is anticipated to be sterically excluded from the CAR-antigen interface. However, native CD45 is not efficiently excluded when the epitope is located at the distal end of the membrane as shown in Fig. 4A, possibly due to an inadequate size difference between the CAR-antigen complex and CD45, which permits its retention within the synapse. To address this issue, they enlarged the extracellular domain of CD45 by conjugating anti-CD45 antibodies via a biotin-streptavidin crosslinking system. This increase in molecular size enhanced the steric hindrance of CD45, thereby promoting its exclusion from the immunological synapse due to spatial incompatibility and enhancing T cell activation [85]. These findings highlight a feasible strategy for modifying CD45 molecular size to optimize CAR-T cell activity and offer novel insights into receptor engineering. To achieve durable and precise CAR-T cell therapy, gene editing technologies have been employed to introduce targeted amino acid substitutions in the extracellular domain of CD45, enabling the selective modulation of antigenic epitopes while preserving their phosphatase activity. This not only opens new avenues for improving CAR-T cell specificity but also helps protect healthy hematopoietic stem cells (HSCs) from CD45-targeted therapies. For example, Nils Wellhausen and colleagues employed CRISPR adenine base editing (ABE8e) to introduce precise single-amino acid substitutions within the extracellular D1 domain of CD45 in both CAR-T cells and HSCs. This modification altered the antigenic epitope recognized by CAR-T cells, which prevented CAR-mediated fratricide of edited T cells while not interfering with CD45-dependent signaling pathways, including Lck kinase activation, thereby ensuring both safety and functional integrity. Preclinical studies demonstrated that these engineered CAR-T cells effectively eliminated patient-derived acute myeloid leukemia, B-cell lymphoma, and T-cell acute lymphoblastic leukemia in xenograft models. Notably, unlike CD45 knockout cells, epitope-edited HSCs retained the ability to engraft, persist, and differentiate in vivo [86]. Building on this concept, Lukas T. Jeker and colleagues developed a strategy to protect HSCs from CD45-targeted ADCs for hematologic malignancies. Using a more flexible adenine base editing system (ABE8e-SpRY), they introduced mutations in the extracellular domain of CD45 on HSCs, particularly K352E and N286D. These modifications created a molecular shield that abolished the binding of cytotoxic ADCs, such as CIM053-SG3376 while preserving the essential phosphatase activity of CD45. This strategy enabled the selective clearance of CD45-positive malignant cells while safeguarding the edited HSCs [87]. Collectively, these studies present a compelling strategy for CD45-based immunotherapy. By introducing CD45 epitope mutations, CAR-T cells, and normal hematopoietic systems can be protected from treatment-related toxicity while preserving the therapeutic agents to recognize and eliminate CD45-positive tumor cells. Modulating the spatial distribution of CD45 The immunological function of CD45 is also associated with its spatial distribution within specific regions of the plasma membrane. This spatiotemporal heterogeneity can modulate the phosphorylation status of immune receptors, thereby directly affecting the signaling threshold and immune responses. Thus, precise modulation of the spatial distribution of CD45 on the plasma membrane has emerged as an important focus in immunotherapeutic research. Various strategies, including DNA nanotechnology and bispecific antibody engineering, have been applied to modulate CD45’s spatial distribution and improve immune responses. For example, to precisely regulate the spatial distribution of membrane proteins such as CD45, Professor Tan developed a versatile DNA nanotechnology platform based on amphiphilic DNA tetrahedrons. The DNA tetrahedron comprises three hydrophobic vertices functionalized with either cholesterol (Tcho3) (targeting lipid-ordered [Lo] domains) or tocopherol (Ttcp3) (targeting lipid-disordered [Ld] domains), while the apex is modified with an anti-CD45 antibody, enabling dynamic and reversible interaction between CD45 and T cell membranes via toehold-mediated strand displacement. By modulating CD45 translocation between Lo and Ld domains, the researchers demonstrated that CD45 exclusion from Lo domains via Ttcp3-mediated targeting to Ld regions enhanced T cell activation, as evidenced by elevated IL-2 secretion and CD69 expression. Conversely, enrichment of CD45 in Lo domains via Tcho3 suppressed T cell activation, demonstrating that the spatial redistribution of CD45 directly modulates T cell signaling (Fig. 3A) [88]. Moreover, based on the angstrom‑level spatial precision of DNA duplexes, Wu et al. experimentally determined that the maximum catalytic radius of protein tyrosine phosphatase receptor type F (PTPRF) is 25.84 nm. Leveraging this finding, they developed a modular aptamer-based phosphatase-recruiting chimera (Apt-RIPR), DNA duplexes were applied as nanometer-scale spacer units (with a physical spacing of 0.34 nm per base pair), assembling the Zaj4a aptamer targeting PTPRF with functional modules that recognize receptor tyrosine kinases (RTKs, such as c-Met or EGFR). This spatial arrangement forces PTPRF to co-localize with the target RTK within the phosphatase catalytic activity range, significantly inhibiting RTK phosphorylation. In A549 cells, 50 nM Apt-RIPR-MET reduced HGF-induced c-Met phosphorylation by approximately 79%, while 200 nM BAAP-TfR1-MET and 500 nM mixed aptamers only achieved approximately 67% and 58% inhibition, respectively. This result highlights the superior efficacy of spatially enforced phosphatase recruitment. By using aptamers as targeting modules with nanomolar binding affinity and DNA‑guided spatial assembly, Apt‑RIPR overcomes key limitations of conventional approaches in blocking ligand‑independent and autophosphorylated RTK signaling, showing clear advantages over ligand‑competitive or kinase active‑site‑directed inhibitors. A further unique strength is the reversible regulation enabled by dynamic DNA hybridization: through introduction of toehold‑containing linkers or responsive sequences, the chimera can be selectively disassembled by competitive complementary strands, thus reversing its inhibition of RTK signaling (Fig. 3B) [89]. Fig. 3(A) DNA tetrahedra functionalized with cholesterols or tocopherols were engineered to target distinct membrane domains for modulating T cell activation. Reproduced from Ma et al. [88] Copyright 2024 J. Am. Chem. Soc. (B) The Zaj4a aptamer targeting PTPRF was linked to an RTK-targeted module via a DNA strand, enabling the localization of RTK within the catalytic radius of PTPRF to enhance its dephosphorylationAdapted from Wu et al. [89] Copyright 2024 J. Am. Chem. Soc. (A) DNA tetrahedra functionalized with cholesterols or tocopherols were engineered to target distinct membrane domains for modulating T cell activation. Reproduced from Ma et al. [88] Copyright 2024 J. Am. Chem. Soc. (B) The Zaj4a aptamer targeting PTPRF was linked to an RTK-targeted module via a DNA strand, enabling the localization of RTK within the catalytic radius of PTPRF to enhance its dephosphorylation Adapted from Wu et al. [89] Copyright 2024 J. Am. Chem. Soc. Furthermore, in addition to the DNA-based approaches for regulating the spatial distribution of CD45 on the membrane, Fernandes et al. constructed bispecific antibodies to facilitate cis-linkage between RTKs and CD45. The tyrosine phosphatase activity of CD45 directly dephosphorylated receptors containing inhibitory tyrosine-based motifs, such as Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM), and Immunoreceptor Tyrosine-based Switch Motif (ITSM), abrogating both ligand-dependent and tonic signaling. Using PD-1 (harboring an ITIM and an ITSM) as a model, the authors engineered a bispecific antibody, RIPR-PD1, comprising an anti-CD45 single-chain variable fragment (scFv) and an anti-PD-1 scFv derived from nivolumab or pembrolizumab. In HEK293 cells and primary T cells, RIPR-PD1 induced PD-1 dephosphorylation in a CD45 catalytic activity-dependent manner, in contrast to conventional anti-PD-1 antibodies, which merely block ligand binding without suppressing persistent intracellular signaling. Furthermore, functionally, RIPR-PD1 increased IL-2 and IFN-γ secretion by ~ 3-fold and ~ 2-fold in activated T cells, respectively. In mouse tumor models, RIPR-PD1 reduced tumor growth by approximately 45% in MC38 colon adenocarcinoma and 50% in KP1 small-cell lung cancer compared to anti-PD-1 therapy. It is worth noting that the RIPR strategy has broad universality: the SIRPα–CD45 bispecific construct enhanced antibody-dependent cell phagocytosis by about 2-fold, validating its applicability (Fig. 4) [90]. To enhance the anti-tumor activity of NK cells, Ren et al. developed a bispecific CD45-natural killer receptor (CD45-NKR) platform, in which single-domain antibodies (VHHs) targeting CD45 and inhibitory NK receptors (e.g., NKG2A, Ly49) are connected via flexible peptide linkers. This design enforces cis-proximity between CD45 and inhibitory receptors at the NK cell-target cell immunological synapse, promoting efficient CD45-mediated dephosphorylation of inhibitory receptors, thereby lifting its inhibition on activation signaling. In vitro assays confirmed that these bispecifics significantly enhanced NK cell cytotoxicity against MHC I-expressing tumor cells (e.g., RMA, B16-OVA), achieving 2–3-fold higher lysis than monospecific NKR-blocking antibodies. Furthermore, this strategy also augmented CD8+ T cell responses by antagonizing NKG2A signaling, offering a promising approach to counteract inhibitory receptor-mediated tumor immune evasion [91]. Fig. 4(A) Schematic depiction of PD-1 phosphorylation before (left) and after (middle) ligand binding and anti-PD-1 antibody blockade (right). (B) RIPR enabled simultaneous binding to the extracellular domains of CD45 and PD-1 for enforcing their spatial proximity and suppressing both ligand-dependent and tonic PD-1 signaling. (C) IL-2 secretion by CAR T cells treated with various molecule after co-culturing with tumor cells. (D) RIPR-SIRPa enhanced antibody-dependent cellular phagocytosis. Adapted from Fernandes et al. [90] Copyright 2020 Nature (A) Schematic depiction of PD-1 phosphorylation before (left) and after (middle) ligand binding and anti-PD-1 antibody blockade (right). (B) RIPR enabled simultaneous binding to the extracellular domains of CD45 and PD-1 for enforcing their spatial proximity and suppressing both ligand-dependent and tonic PD-1 signaling. (C) IL-2 secretion by CAR T cells treated with various molecule after co-culturing with tumor cells. (D) RIPR-SIRPa enhanced antibody-dependent cellular phagocytosis. Adapted from Fernandes et al. [90] Copyright 2020 Nature Furthermore, studies have shown that antibody agonists can also modulate the spatial distribution of CD45. These antibodies can dynamically exclude CD45 from receptor microdomains, which are functional regions of the cell membrane enriched in receptors and signaling molecules and play a critical role in cellular signaling. This process alleviates the inhibitory effect of CD45 on the phosphorylation sites of immune receptors such as CD28 and initiates downstream signaling cascades. This mechanism not only explains the dependence of CD28 agonist antibodies on spatial exclusion but also reveals a potential mechanism by which certain antibodies, such as nivolumab, can exhibit agonistic effects under specific conditions by modulating the spatial distribution of CD45. The efficiency of CD45 exclusion directly correlated with functional output: strong agonists achieved approximately 1.1- to 6-fold greater CD45 exclusion compared to weak or non-agonistic antibodies, leading to increased IL-2 production and T cell activation. Further studies suggest that antibody engineering through the modulation of molecular size or epitope specificity can precisely control the exclusion efficiency of CD45, thereby providing a theoretical framework for the development of novel immunotherapeutic agonists and antagonists [92]. CD45-targeted drug delivery systems CD45 has been explored as a target for drug delivery systems, particularly in immunotherapy. By selectively targeting CD45, these drug systems can selectively eliminate malignant hematologic tumors or modulate immune responses with high specificity, thereby reducing off-target effects on healthy tissues. This section will explore the design and therapeutic potential of CD45-targeted delivery systems, including CD45-targeted ADCs, ARCs, and immunocytokine fusions (i.e., engineered constructs that combine cytokines with targeting antibodies, such as αCD45-cytokine fusions) (Fig. 5). Fig. 5Schematic representation of CD45 antibody-based drug delivery systems, including ADC, ARC, and immunocytokine fusion. Figures were created using BioRender (https://www.biorender.com/) Schematic representation of CD45 antibody-based drug delivery systems, including ADC, ARC, and immunocytokine fusion. Figures were created using BioRender (https://www.biorender.com/) Antibody-drug conjugate (ADC) As a novel targeted therapeutic system, ADC enables the selective killing of specific cell populations through the precise coupling of monoclonal antibodies with cytotoxic drugs. It primarily relies on the highly specific binding between the antibody variable region and the target cell surface antigen epitope [93]. As a protein widely expressed on the surface of hematopoietic cells, CD45-targeted ADCs have demonstrated unique advantages in leukemia, HSC transplantation, and myeloid cell depletion. Recent preclinical studies have provided strong evidence for the efficacy of CD45-targeted ADCs. For example, Yeung et al. systematically compared the efficacy differences between cleavable (sg3249) and non-cleavable (sg3376) linkers by conjugating rat IgG2b anti-human CD45 monoclonal antibodies YTH24.5 and YTH54.12 with pyrrolo [3,4-b]quinazoline (PBD) dimeric toxins. The study demonstrated that ADCs with acid-sensitive cleavable linkers efficiently released PBD toxins under the effect of lysosome-specific enzymes, significantly inhibiting the proliferation of CD45+ leukemia cells and delaying leukemia progression in tumor-bearing animal models [94]. Meanwhile, Palchaudhuri et al. innovatively conjugated CD45 antibodies with the immunosuppressant 30F11 to construct an ADC, which exhibited dual regulatory effects in a mouse allogeneic HSC transplantation model by clearing host immune cells while preserving the function and engraftment efficiency of donor HSC [95]. Clinical trials have further validated the therapeutic potential of CD45-targeted ADCs. Gillard et al. demonstrated that a single dose of CD45-ADC loaded with PBD cytotoxic payloads has efficiently eliminated autoreactive CD4+ T cells [96]. Additionally, Gustafsson et al. used a CD45-ADC loaded with PBD to achieve targeted depletion of central nervous system-resident myeloid cells (CD45+ CD11b+ Ly6C+ TRM) in a humanized NOD-scid-gamma (NSG) mouse model, with depletion efficiencies ranging from 40% to 95% [97]. Although existing models still require optimization, these groundbreaking advances suggest the rapid translation of CD45-targeted ADCs from basic research to clinical applications, opening new avenues for the treatment of leukemia, transplant-related immune modulation, and other diseases. Antibody-radionuclide conjugate (ARC) ARC functions by precisely coupling targeting antibodies with radionuclides, which apply α-particle radiation to induce DNA double-strand breaks, thereby mediating cell killing [98]. Due to the ubiquitous expression on hematopoietic cells, CD45 has become a critical target for ARCs in the treatment of hematological diseases. Clinical studies have demonstrated that anti-CD45 ARCs can effectively target and eliminate CD45+ cells, showing significant potential in treating hematological malignancies such as leukemia. For instance, an ARC based on an anti-CD45 monoclonal antibody conjugated to iodine-131 (131I) showed remarkable efficiency in clinical trials involving Hodgkin’s lymphoma patients. After autologous stem cell transplantation, the patients had a 3-year progression-free survival rate of 68%, despite dose-limiting pulmonary toxicity being observed [99]. To enhance therapeutic efficacy and reduce side effects, researchers have developed novel radionuclide systems, such as Yttrium-90 (90Y), which have shown improved efficacy in treating acute myeloid leukemia. In clinical trials, 90Y-based therapy resulted in a 2-year overall survival rate of 41%, without increasing the incidence of graft-versus-host disease (GVHD) [100]. Studies have found that CD45-ARCs effectively target and eliminate CD45+ leukemia cells in both human [101] and murine leukemia models [102–104]. These studies suggest that CD45-targeted therapeutic strategies, combined with precise radionuclide design, offer novel treatment approaches for relapsed or refractory hematological tumors and may provide insights into the treatment of other immune-related diseases. Recent studies have shown that CD45 is not only a critical target for disease therapies but also provides precise guidance for disease diagnosis through imaging applications. For example, the CD45-positron emission tomography (PET) probe developed by Salehi Farid et al. enabled non-invasive dynamic monitoring of CD45+ cell infiltration. In models of inflammatory bowel disease and acute respiratory distress syndrome, CD45-PET successfully localized inflammation with high sensitivity, offering real-time insights into treatment efficacy. In a GVHD model, the CD45-PET probe tracked the distribution of humanized murine CD45+ immune cells, offering critical information for optimizing treatment regimens. Additionally, CD45-PET exhibited higher sensitivity in distinguishing inflammation from tumor metabolic activity (e.g., 18F-FDG-PET), aiding in reducing diagnostic errors during treatment [105]. In conclusion, through optimized ARC designs, ARCs efficiently target and eliminate CD45+ cells. Coupled with imaging technologies such as CD45-PET, these strategies facilitate real-time monitoring of therapeutic efficacy. The integration of these technologies not only offers new treatment strategies for malignant blood diseases but also provides a theoretical foundation for the development of personalized treatment plans. However, despite promising early clinical results, improving efficacy and reducing side effects, particularly long-term radiation toxicity, remains a key issue that future research must address. Immunocytokine fusions Cytokines play essential roles in immune regulation through cascade signaling pathways. However, dose-limiting toxicity severely restricts their clinical application, particularly in the treatment of advanced tumors. While local delivery strategies can reduce systemic toxicity and induce regression of primary lesions, they fail to suppress distant metastases. CD45, as a pan-leukocyte antigen, is abundantly expressed on lymphocytes and exhibits unique membrane anchoring properties. Notably, anti-CD45 antibodies can selectively bind to target cells without undergoing endocytosis [106]. Leveraging this unique property, researchers developed genetically engineered immunocytokine fusions, which combined cytokines with anti-CD45 antibodies. For instance, Darrell J. Irvine designed an αCD45-IL-15/IL-12 immunocytokine. First, the anti-CD45 antibody domain facilitated CD45-mediated membrane anchoring, enabling the fusion protein to stably accumulate within the tumor microenvironment and drain lymph nodes, thereby significantly extending its biological half-life. In addition, the cytokine domain was released in a gradient-dependent manner through restricted diffusion, promoting the progression of antigen-specific CD8+ T cells from initial activation to full functional maturation. This “directional release” mechanism effectively mitigated the systemic toxicity of conventional cytokine therapies, while markedly increasing the tumor-infiltrating lymphocyte population and eradicating untreated metastatic lesions by establishing durable immunological memory [107]. A comprehensive comparison of CD45-targeted ADCs, ARCs, and immunocytokine fusions in terms of therapeutic modality, mechanism of action, preclinical applications, and challenges is summarized in Table 2. Table 2Comparison of CD45-targeted delivery systemsModalityADCARCImmunocytokine fusionTargeting GroupAnti-human CD45 monoclonal antibodies (e.g., YTH24.5, YTH54.12)BC8(Ig) G2cTherapeutic AgentsChemotherapeutics (e.g., pyrrolobenzodiazepines) or immunosuppressantsRadionuclides, β-emitters (131I, 90Y)Immunomodulatory cytokines (e.g., IL-15Sa, IL-12)Mechanism of ActionUpon internalization, toxins are released to induce DNA damage and deplete CD45+ cellsLocal radiation induces DNA double-strand breaks to eliminate CD45+ cellsLocal cytokine release enhances T/NK cell effector functions and induces systemic immune memoryPreclinical ModelsLeukemia, multiple sclerosisHodgkin lymphoma, acute myeloid leukemiaColorectal cancer, melanomaChallengesDrug resistance off-target toxicity (e.g., HSC damage)Risk of long-term radiation toxicity (e.g., pulmonary fibrosis), dose-limiting organ damageImmunosuppressive tumor microenvironment, potential cytokine receptor desensitizationReferences[94]–[98][99]–[106][107],[108](Note: Immunocytokine fusions refer to genetically engineered constructs combining cytokines with targeting antibodies, such as αCD45-cytokine fusions) Table 2Comparison of CD45-targeted delivery systemsModalityADCARCImmunocytokine fusionTargeting GroupAnti-human CD45 monoclonal antibodies (e.g., YTH24.5, YTH54.12)BC8(Ig) G2cTherapeutic AgentsChemotherapeutics (e.g., pyrrolobenzodiazepines) or immunosuppressantsRadionuclides, β-emitters (131I, 90Y)Immunomodulatory cytokines (e.g., IL-15Sa, IL-12)Mechanism of ActionUpon internalization, toxins are released to induce DNA damage and deplete CD45+ cellsLocal radiation induces DNA double-strand breaks to eliminate CD45+ cellsLocal cytokine release enhances T/NK cell effector functions and induces systemic immune memoryPreclinical ModelsLeukemia, multiple sclerosisHodgkin lymphoma, acute myeloid leukemiaColorectal cancer, melanomaChallengesDrug resistance off-target toxicity (e.g., HSC damage)Risk of long-term radiation toxicity (e.g., pulmonary fibrosis), dose-limiting organ damageImmunosuppressive tumor microenvironment, potential cytokine receptor desensitizationReferences[94]–[98][99]–[106][107],[108](Note: Immunocytokine fusions refer to genetically engineered constructs combining cytokines with targeting antibodies, such as αCD45-cytokine fusions) Comparison of CD45-targeted delivery systems (Note: Immunocytokine fusions refer to genetically engineered constructs combining cytokines with targeting antibodies, such as αCD45-cytokine fusions) CD45 as a drug-anchoring site on cell carriers Due to its stable transmembrane localization and ubiquitous expression among immune cells, CD45 presents distinct advantages as a drug-loading site on cellular carriers. Professor Darrell J. Irvine’s team has made significant advancements in this area of research, continually exploring and optimizing the application of CD45 for drug loading on cell surfaces. Early studies focused on the thiol-rich extracellular domain of CD45 and developed a maleimide-thiol covalent conjugation strategy to anchor maleimide-functionalized lipid nanoparticles, such as multilamellar liposomes or lipid-coated polymeric nanoparticles, onto the surface of immune cells through chemical reactions. Stable drug loading was achieved through a two-step procedure: First, covalent bonds are formed via thiol-alkene addition, anchoring the nanoparticles to the surface of T cells or HSCs. Subsequently, residual active sites are blocked with thiol-terminated polyethylene glycol to prevent nonspecific protein adsorption. This anchoring strategy creates a “drug reservoir” capable of co-migrating with the host cells. For instance, nanoparticles loaded with the glycogen synthase kinase-3 (GSK-3) inhibitor TWS119 significantly accelerated hematopoietic reconstitution following HSC transplantation without impairing their multilineage differentiation potential toward both myeloid and lymphoid lineages. Moreover, nanoparticles carrying IL-15 superagonist complexes (IL-15Sa/IL-21) continuously released cytokines, resulting in an 81-fold increase in the peak number of T cell expansion, as quantified by bioluminescent photon counts on day 6, compared to unmodified T cells. This enhanced proliferative response enabled the effective clearance of established solid tumors [108]. With a deeper understanding of the dynamic reorganization mechanisms of the immunological synapse, researchers have further developed synapse-responsive maleimide-functionalized multilamellar liposomes (MLVs) as a key tool for modulating T cell-tumor cell interactions. The immunological synapse is a tightly organized microdomain that enriches inhibitory phosphatases like Shp1/2. However, systemic administration of the Shp1/2 inhibitor NSC-87,877 faces two major challenges: the dense structure of the synapse physically restricts drug entry, and off-target inhibition of Shp1/2 in non-tumor tissues may trigger autoimmune toxicity. To address these issues, MLVs were covalently conjugated to CD45 of T cell surfaces via maleimide-thiol chemistry. By optimizing surface charge and maleimide modification density, MLVs loaded with NSC-87,877 stably anchored resting T cells in vitro. During T cell migration, MLVs accumulated at the uropod, a specialized rear structure enriched with adhesion molecules such as LFA-1 and CD2. Upon antigen recognition, MLVs redistributed from the uropod to the T cell-tumor cell contact zone, co-localizing with CD45 in the peripheral supramolecular activation cluster (pSMAC). This process differs from the exclusion of CD45 from the cSMAC (the T cell receptor complex localizes), CD45 remains associated with the pSMAC/uropod domain. This synaptic responsiveness resulted in a higher accumulation of T cells within tumors compared to systemic administration of free NSC-87,877. Meanwhile, in the prostate cancer model, localized Shp1/2 inhibition enhanced T cell clonal expansion and effectively alleviated tumor-induced T cell exhaustion. Notably, this approach leverages CD45’s natural synaptic polarization toward the pSMAC/uropod rather than physical anchoring, ensuring precise coupling of drug release with T cell activation and minimizing off-target effects in non-tumor tissues (Fig. 6) [109]. To address the narrow therapeutic window of conventional cytokine therapies, the research team developed redox-responsive protein nanogels (NGs) that utilize the stability of the CD45 transmembrane region to construct a signal-triggered release system. IL-15SA was cross-linked into nanogels using a disulfide-containing crosslinker (NHS-SS-NHS) and non-covalently anchored to the surface of T cells via anti-CD45 antibodies. Upon tumor antigen recognition, the elevated surface redox potential of activated T cells triggers disulfide bond cleavage, enabling site-specific release of IL-15SA. In a melanoma model, this strategy resulted in a 16-fold increase in intratumoral T cell proliferation, while systemic toxicity was reduced eightfold compared to free IL-15SA. This approach leverages the stable transmembrane localization of CD45 to anchor nanogels and incorporates redox-responsive materials science, thereby enabling precise coupling between T cell activation and drug release [110]. Fig. 6(A) Left: MLVs were co-localized with CD45 in the pSMAC, enabling localized drug delivery to stimulatory receptors while protecting downstream signaling pathways from inhibitory molecules by suppressing synaptic phosphatases such as Shp1/2. Right: Representative image of nanoparticles bound to surface proteins on T cells. (B) Confocal images of T cells and tumor cells forming synaptic contacts. (C) Mean photon counts over time measured over the prostate area from each animal (illustrated by the bioluminescent acquisition at right). Adapted from Stephan et al. [109] Copyright 2012 Biomaterials (A) Left: MLVs were co-localized with CD45 in the pSMAC, enabling localized drug delivery to stimulatory receptors while protecting downstream signaling pathways from inhibitory molecules by suppressing synaptic phosphatases such as Shp1/2. Right: Representative image of nanoparticles bound to surface proteins on T cells. (B) Confocal images of T cells and tumor cells forming synaptic contacts. (C) Mean photon counts over time measured over the prostate area from each animal (illustrated by the bioluminescent acquisition at right). Adapted from Stephan et al. [109] Copyright 2012 Biomaterials Conclusion and discussion CD45, a critical receptor-type protein tyrosine phosphatase expressed on leukocytes, plays a central role in immune regulation by modulating the activation thresholds of diverse immune receptors. Aberrations in CD45 function have been closely associated with autoimmune diseases, hematologic malignancies, and solid tumors. Multiple therapeutic strategies targeting CD45 have been developed, primarily focusing on the dynamic regulation of its expression, structural isoform diversity, and spatial organization on the plasma membrane. Beyond its role as a therapeutic target, the unique molecular properties of CD45 also confer substantial potential for drug delivery applications. Its high and specific expression on leukocytes makes it an attractive anchoring molecule for ADCs, ARCs, and other targeted delivery systems, thereby enhancing immune cell–specific targeting efficiency. With the growing interest in living cell-based delivery platforms, CD45 further represents a promising drug-loading site due to its high surface abundance and relative resistance to endocytosis. Despite these advantages, the clinical translation of CD45-based therapeutic strategies still faces several major challenges. For example, although artificial manipulation of CD45 membrane localization represents a promising approach to modulate immune signaling, it may also perturb the dynamics of neighboring receptors, leading to unintended alterations in receptor phosphorylation. A more comprehensive understanding of the spatiotemporal mechanisms governing CD45 membrane dynamics is therefore required. Integrating molecular dynamics simulations with live-cell imaging may improve the predictability and controllability of membrane-targeted interventions. In addition, although DNA tetrahedra and related constructs provide exceptional programmability for nanoscale control of membrane protein positioning, their in vivo stability and pharmacokinetics remain limited by nuclease-mediated degradation and rapid renal clearance following systemic administration. Moreover, repeated administration may trigger innate immune responses, and their high production cost and synthetic complexity further hinder large-scale application. Therefore, there is a need to develop structurally stable and scalable tools for membrane protein regulation to facilitate clinical translation [111]. Although CD45-targeted delivery systems have shown effective depletion of leukemia cells, host immune cells, or pathogenic bone marrow cells, most ADC platforms currently reported are still at the preclinical stage. The main obstacle to its clinical application is the broad expression of CD45 on normal hematopoietic cells, which can lead to prolonged cytopenia, impaired bone marrow reserve, delayed immune reconstitution, and the risk of damage to hematopoietic stem cells and progenitor cells. Therefore, biomarker-guided patient monitoring, including fieepayload levels, genotoxicity, hematologic parameters, lymphocyte subset reconstitution, and inflammatory cytokine profiles, will be essential. In contrast, CD45-targeted ARC has entered clinical evaluation for recurrent hematological malignancies. However, its broader application remains constrained by non-specific organ exposure and the inherent limitations of radionuclide therapy. Future ARC will benefit from optimized isotope selection, individualized dosimetry, and long-term toxicity assessment [112, 113]. For CD45-anchored cytokine delivery systems, the localized retention concept is attractive, but systemic cytokine leakage and unintended modulation of activation thresholds in bystander leukocytes require careful evaluation. Long-term immune monitoring, including cytokine profiling and T cell functional assessment, will be necessary during clinical translation. To avoid the potential safety concerns of CD45-based therapies, epitope or gene editing have shown good preclinical potential by protecting HSC [114]. Nevertheless, broader clinical adoption will require careful evaluation of editing efficiency and long-term hematopoietic stability. Potential complications such as clonal expansion of edited stem cell populations, off-target effects, immunogenicity of modified epitopes, and delayed marrow dysfunction should be specifically monitored in future studies [115]. In summary, real-time immune monitoring and adaptive treatment optimization will be critical for minimizing the risks associated with CD45-based therapies and drug delivery systems. In conclusion, CD45 exhibits substantial potential for clinical translation as both a therapeutic target and a site for drug targeting and loading. Through a multidimensional analysis spanning molecular mechanisms to translational applications, this review highlights how CD45-based strategies support the treatment of autoimmune diseases, hematologic malignancies, and related disorders, with a consolidated overview of these aspects provided in Table 3. Future progress will depend on translating strong biological rationale into clinically viable systems with durable efficacy, favorable safety profiles, and scalable manufacturability. Table 3Summary of CD45 protein biological functions, therapeutic regulation strategies, and drug delivery applicationsCategoryKey mechanisms/ FunctionsRepresentative examplesSignificanceBiological functions on leukocytesRegulation of Src family kinases (Lck, Lyn, Hck) and the JAK–STAT pathwayT cells: bidirectional regulation of Lck phosphorylation;B cells: promotion of Lyn activation;NK/DCs: regulation of basal SFK activity; macrophages/neutrophils: constraining the activation of Hck and LynParticipation in signal transduction, activation threshold control, and immune cell functionTherapeutic regulation strategiesExpression modulation (RNAi, CRISPR);Structural modification (epitope editing, size engineering);Spatial redistribution (DNA nanotechnology, bispecific antibodies)LNP–siRNA silencing of myeloid CD45; CRISPR-edited CD45 for HSC protection;RIPR–PD1 bispecific antibody and DNA tetrahedron–mediated CD45 relocation for T cell activationApplication for disease treatmentDrug delivery applicationsAs a drug-targeting site;As a drug-anchoring site on cell carriersCD45-ADC, CD45-ARC, αCD45–IL-15/IL-12 immunocytokines; CD45-anchored liposomes/redox-responsive nanogels/synapse-responsive MLVsElimination of CD45⁺ malignant cells; Enhance immune cell functionChallenges and future directionsChallenges: off-target toxicity; immune dysregulation; complexity and unpredictability of spatial redistribution interventions.Future Directions: epitope editing to protect normal hematopoietic cells, reversible regulation strategies, integration of molecular dynamics simulations with live-cell imaging to enhance the predictability of membrane structure interventions Table 3Summary of CD45 protein biological functions, therapeutic regulation strategies, and drug delivery applicationsCategoryKey mechanisms/ FunctionsRepresentative examplesSignificanceBiological functions on leukocytesRegulation of Src family kinases (Lck, Lyn, Hck) and the JAK–STAT pathwayT cells: bidirectional regulation of Lck phosphorylation;B cells: promotion of Lyn activation;NK/DCs: regulation of basal SFK activity; macrophages/neutrophils: constraining the activation of Hck and LynParticipation in signal transduction, activation threshold control, and immune cell functionTherapeutic regulation strategiesExpression modulation (RNAi, CRISPR);Structural modification (epitope editing, size engineering);Spatial redistribution (DNA nanotechnology, bispecific antibodies)LNP–siRNA silencing of myeloid CD45; CRISPR-edited CD45 for HSC protection;RIPR–PD1 bispecific antibody and DNA tetrahedron–mediated CD45 relocation for T cell activationApplication for disease treatmentDrug delivery applicationsAs a drug-targeting site;As a drug-anchoring site on cell carriersCD45-ADC, CD45-ARC, αCD45–IL-15/IL-12 immunocytokines; CD45-anchored liposomes/redox-responsive nanogels/synapse-responsive MLVsElimination of CD45⁺ malignant cells; Enhance immune cell functionChallenges and future directionsChallenges: off-target toxicity; immune dysregulation; complexity and unpredictability of spatial redistribution interventions.Future Directions: epitope editing to protect normal hematopoietic cells, reversible regulation strategies, integration of molecular dynamics simulations with live-cell imaging to enhance the predictability of membrane structure interventions Summary of CD45 protein biological functions, therapeutic regulation strategies, and drug delivery applications T cells: bidirectional regulation of Lck phosphorylation; B cells: promotion of Lyn activation; NK/DCs: regulation of basal SFK activity; macrophages/neutrophils: constraining the activation of Hck and Lyn Expression modulation (RNAi, CRISPR); Structural modification (epitope editing, size engineering); Spatial redistribution (DNA nanotechnology, bispecific antibodies) LNP–siRNA silencing of myeloid CD45; CRISPR-edited CD45 for HSC protection; RIPR–PD1 bispecific antibody and DNA tetrahedron–mediated CD45 relocation for T cell activation As a drug-targeting site; As a drug-anchoring site on cell carriers Challenges: off-target toxicity; immune dysregulation; complexity and unpredictability of spatial redistribution interventions. Future Directions: epitope editing to protect normal hematopoietic cells, reversible regulation strategies, integration of molecular dynamics simulations with live-cell imaging to enhance the predictability of membrane structure interventions